Multinational Association of Supportive Care in Cancer (original) (raw)
Related papers
Many studies have been conducted about dietary interventions aimed at preventing cancer. The American Cancer Society has published guidelines on diet, nutrition and cancer prevention, which are updated periodically as new evidence emerges, and other groups, too, have issued statements or guidelines about nutritional strategies to prevent cancer. Much less is known, however, about optimal nutrition for cancer survivors. This report looks at the different phases of cancer survivorship, from active treatment to advanced disease, and presents existing evidence from which informed decisions can be made regarding dietary choices. Popular complementary and alternative methods related to dietary intervention are reviewed. Nutrition information is also provided according to common cancer sites. As this is an area that requires survivors and health care providers to communicate effectively, a special section on " frequently asked questions " is provided for use as a patient
Annals of Oncology, 2014
The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries. Medical oncology is a core member of the MDT and offers cancer patients a comprehensive and systemic approach to treatment and care, while ensuring evidence-based, safe and cost-effective use of cancer drugs and preserving the quality of life of cancer patients through the entire 'cancer journey'. Medical oncologists are also engaged in clinical and translational research to promote innovation and new therapies and they contribute to cancer diagnosis, prevention and research, making a difference for patients in a dynamic, stimulating professional environment. Medical oncologists play an important role in shaping the future of healthcare through innovation and are also actively involved at the political level to ensure a maximum contribution of the profession to Society and to tackle future challenges. This position paper summarises the multifarious and vital contributions of medical oncology and medical oncologists to today's and tomorrow's professional cancer care.
Supportive Care Organization in France: a national in-depth survey among patients and oncologists
Supportive Care in Cancer, 2017
Purpose Medical doctors' (MDs), but not patients', perception of supportive care in cancer (SCC) in France has been previously assessed in a national survey. This study evaluated MDs and patients' perceptions of the SCC organization and implementation in France. Methods The French SCC Association conducted two observational studies: study 1 (S1), containing a 30-point questionnaire sent to 2263 MDs, and study 2 (S2), containing a 40point questionnaire sent to 2000 patients. Results Overall, 711 MDs completed S1 and 1562 patients completed S2. In S1, 81% of MDs reported relying on a SCC organization and 76% attended SCC multidisciplinary discussions. MDs considered palliative (98%), psychological (98%), and social care (98%) as the top 3 SCC areas of importance for patients. In contrast, patients' priorities were psychology (61%), nutrition (55%) and organization of intake consultations (55%). The concept of SCC was familiar to 34% of patients; according to MDs, this concept was introduced mainly by MDs (78%) and admission nurses (41%). Outpatients identified as professional resources for SCC information general practitioners (84%), nurses (58%), and pharmacists (52%). Patients reported supportive treatment being prescribed in 63% of cases, with 64% receiving information on the negative side-effects. Among MDs, 87% reported proposing palliative and 41% adjuvant SCC treatment. Furthermore, 72% of MDs recommended SCC treatment at the metastatic stage, and 36% immediately following diagnosis. Discussion Oncologists play a vital role in enhancing SCC efficacy. This can be increased by implementing a multidisciplinary integrated approach or by assuring the availability of patient information.
International Journal of Pharmacy and Pharmaceutical Sciences, 2017
Objective: To study the prescribing patterns of chemotherapeutic drugs, concomitant drugs and to determine the drug-related problems in cancer patients. Methods: A prospective and retrospective observational study was conducted over a period of 6 mo in a tertiary care teaching hospital, Pune after ethical approval and informed consent. Patients were then interviewed for patient information like demographics, treatment, and associated drug related problems using specially designed proforma and then required data was introduced in Microsoft excel spreadsheets. Results: Out of 60 patients 50 were enrolled in this study during which 9 different sites of cancer were examined. The maximum number of patients with cancer resides in the age group of 51-60 y (32%) and more common in females in 27 (54%). The most prevalent risk factor and co-morbidity encountered were tobacco chewing 13 (26%) and hypertension 8 (16%), respectively. On the further evaluation of data, the findings suggested that the majority of patients were prescribed with an alkylating group of anti-neoplastic agents, paclitaxel+platinum-based compound regimen, and the drug paclitaxel. On screening, 167 drug interactions were observed, of these most of the interactions were in the moderate category. The most common organ system affected was gastrointestinal system 135 (30.80%) whereas the prevalent toxicity was hyperuricemia. Polypharmacy was not observed, whereas antacid (ranitidine) was frequently prescribed during hospitalisation and discharge. Conclusion: This study has highlighted certain facts and drawbacks in medication-related care which can be addressed by conducting future studies in cancer care in order to provide patient-specific outcomes.
Breast Care, 2008
Brustkrebsbehandlung · Untersuchung der Gesundheitspflege · Adjuvante Therapie · Brustkrebs, metastatischer · Einhaltung von Richtlinien Zusammenfassung Hintergrund: Die Organgruppe Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat eine landesweite 3-Phasen-Analyse zu Struktur und Standard der medizinischen Versorgung von Brustkrebspatienten im Zeitraum von 2002 (4. Quartal) bis 2004 (4. Quartal) durchgeführt. Das Ausmaß der Umsetzung nationaler und internationaler Behandlungsempfehlungen in der allgemeinen klinischen Praxis war bisher noch nie in einem interdisziplinären Ansatz bewertet worden, und bisher waren keine verlässlichen Daten zur Versorgungsstruktur dieser Patienten in Deutschland veröffentlicht worden. Patienten und Methoden: Das Projekt umfasste primären Brustkrebs in der adjuvanten und neoadjuvanten Situation sowie metastatischen Brustkrebs. Wir präsentieren die Ergebnisse der Phase III der AGO-Analyse, welche auf einem von der Organkommission Mamma im 4. Quartal des Jahres 2004 erstellten Gutachten basieren. Ergebnisse: Die Auswertung der Daten zeigt, dass in bestimmten Bereichen auf Richtlinien basierende Behandlungsansätze sehr verlässlich angewandt werden. Dies ist besonders relevant in Hinsicht auf die Struktur der adjuvanten Behandlung bei frühem Brustkrebs. Im Gegensatz dazu erschwert die Komplexität des interdisziplinären Behandlungsansatzes bei metastatischem Brustkrebs solch eine einfache Analyse. Schlussfolgerung: Die vorliegende AGO-Analyse war der erste Versuch, die Behandlung von Patientinnen mit metastatischem Brustkrebs systematisch zu analysieren. Ein grundlegendes Problem ist weiterhin, dass unabhängig vom Tumorstadium zu wenige Patienten im Rahmen randomisierter klinischer Studie behandelt werden. Die Mission der AGO-Organkommission Mamma ist die Langzeitüberwachung von gebräuchlichen Therapieansätzen bei Brustkrebs auf der Basis der hier diskutierten Beobachtungen, was letztendlich der Optimierung der Behandlungsqualität in Deutschland dienen sollte.
Klaassen_et_al-2018-European_Journal_of_Cancer_Care.pdf
Personalising aftercare for curatively treated breast cancer patients is expected to improve patient satisfaction with care. A patient decision aid can support women in making decisions about their aftercare trajectory, but is currently not available. The aim of this study was to assess the needs of patients and health professionals with regard to an aftercare decision aid to systematically develop such a decision aid. Focus groups with patients and individual interviews with health professionals were digitally recorded and coded using the Framework analysis. Although most patients felt few aftercare options were available to them, health professionals reported to provide various options on the patients’ request. Patients reported difficulty in expressing their need for options to their health professional. Although most patients were unfamiliar with decision aids, the majority preferred a paper-based patient decision aid, while most health professionals preferred an online tool. The practical implications for the intended patient decision aid are: that a digital tool with paper-based element should be developed, the patient decision aid should facilitate both rational and intuitive processes and should provide insight in patients’ preferences concerning aftercare to discuss these explicitly.